A rationale for an individualized administration frequency of epoetin β: A pharmacological perspective

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 6, 2002, Pages 13-16

  Locatelli, F ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anaemia; End stage renal disease; Epoetin ; Equivalence; Erythropoietin; Haematocrit

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOCRIT; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HUMAN; INJECTIONS, SUBCUTANEOUS; PRACTICE GUIDELINES; TIME FACTORS; ERYTHROPOIETIN, RECOMBINANT; HUMANS;

EID: 0036319921     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Assessing guidelines for use in family practice
2. Clinical Practice Guidelines for the treatment of anemia of chronic renal failure
3. Clinical Practice Guidelines for anemia of chronic kidney disease: Update 2000
4. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure
5. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
6. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?
7. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients
8. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
9. Subcutaneous erythropoietin results in lower doses and equivalent hematocrit levels among adult hemodialysis patients: Results from End-Stage Renal Disease Core Indicators Project
10. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
11. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients?
12. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
13. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients
14. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
15. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
16. Once weekly compared with three times weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic equivalence study
17. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
18. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products
19. ICH Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials